Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies

Investigation of Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02434809

Enrollment

Registered

2015-05-05

Start date

2015-04-01

Completion date

2027-04-01

Last updated

2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Respiratory Motion-Corrected Cone-Beam CT, Radiation, 14-225

Brief summary

The first purpose of this study is to test a new computer program that reduces the blurring in the cone-beam CT scan and helps the doctor to better locate the tumor. The investigators want to find out what effects, good and/or bad, that this has on the patient and the way we treat the cancer in the lungs. The second purpose of this study is to test how well this computer program tracks markers in the images, compared to using radio signals to follow the markers.

Interventions

PROCEDUREBronchoscopic Implantation

Calypso transponders

DEVICECone-Beam CT-Guided

RADIATIONstereotactic body radiation treatments

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologic proof of malignancy suitable for thoracic radiation therapy * Patient is planning to undergo radiation therapy for primary or recurrent malignancies of the lung or metastatic malignancies to the lung. * Age ≥ 18 years old * Karnofsky Performance Status ≥ 60% * At least part of the tumor must be visible as observed in a diagnostic or planning CT. * Able to have bronchoscopic placement of Calypso transponders as confirmed on a recent (within the past 8 weeks) CT scan.

Exclusion criteria

* Patients with clinically significant active infections. * Bronchiectasis in the region of the intended implantation. * History of hypersensitivity to nickel. * Other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical study. * Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines * Unable to tolerate anesthesia or sedation * Enrolled in any other clinical studies the investigator believes to be in conflict with this investigation. * Female patients who are pregnant or nursing

Design outcomes

Primary

Measure	Time frame	Description
successful Calypso transponder implantation	1 year	The RapidTrack algorithm will be considered successful if the centroid position of the Calypso transponders, as determined by the RapidTrack algorithm, are within 2 mm of the positions determined by the Calypso system 95% of the time.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORZhang Peng, PhD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026